Zedsen develops non-invasive sensor technology that unobtrusively gathers key biological signals from the bloodstream. The data is used to produce hyper-personalised insights and tailored support around health, fitness and diet for individual users. The company is led by CEO Daniel Honeywell and CTO Dr. Caroline Hargrove. Zedsen intends to use recent funding to continue expanding its operations and business reach. Financially, the company completed a $12M Series B at a $110M valuation, signaling investor confidence in its technology and growth plans.

Total raised

$12M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2021